Literature DB >> 25324145

[Ketamine as antidepressant: the current study situation].

P S Ritter1, M Bauer, M Pilhatsch.   

Abstract

The treatment of depressive episodes is characterized by a delay in response of antidepressant medications and high rates of therapeutic failure. In recent years several open and five controlled trials have demonstrated the antidepressant efficacy of ketamine for major depression. In addition a recent study established the utility of nasal ketamine which may render the necessity of intravenous administration obsolete. The current state of evidence is reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25324145     DOI: 10.1007/s00115-014-4132-5

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  26 in total

1.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

2.  Chronic ketamine administration modulates midbrain dopamine system in mice.

Authors:  Sijie Tan; Wai Ping Lam; Maria S M Wai; Wan-Hua Amy Yu; David T Yew
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

3.  Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome.

Authors:  Michael E Goldberg; Richard Domsky; Denise Scaringe; Robert Hirsh; Jessie Dotson; Imran Sharaf; Marc C Torjman; Robert J Schwartzman
Journal:  Pain Physician       Date:  2005-04       Impact factor: 4.965

4.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

Review 5.  The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.

Authors:  Lisa M Monteggia; Erinn Gideons; Ege T Kavalali
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

6.  Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  Daniel B Carr; Leonidas C Goudas; William T Denman; Daniel Brookoff; Peter S Staats; Loralie Brennen; Geoff Green; Randi Albin; Douglas Hamilton; Mark C Rogers; Leonard Firestone; Philip T Lavin; Fred Mermelstein
Journal:  Pain       Date:  2004-03       Impact factor: 6.961

7.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

8.  A randomized controlled trial of intranasal ketamine in major depressive disorder.

Authors:  Kyle A B Lapidus; Cara F Levitch; Andrew M Perez; Jess W Brallier; Michael K Parides; Laili Soleimani; Adriana Feder; Dan V Iosifescu; Dennis S Charney; James W Murrough
Journal:  Biol Psychiatry       Date:  2014-04-03       Impact factor: 13.382

9.  [S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations].

Authors:  A Pfennig; T Bschor; T Baghai; P Bräunig; P Brieger; P Falkai; D Geissler; R Gielen; H Giesler; O Gruber; I Kopp; T D Meyer; K H Möhrmann; C Muche-Borowski; F Padberg; H Scherk; D Strech; M Bauer
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

Review 10.  Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties.

Authors:  P A Zunszain; M A Horowitz; A Cattaneo; M M Lupi; C M Pariante
Journal:  Mol Psychiatry       Date:  2013-07-23       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.